2.10
+0.04(+1.94%)
Currency In USD
| Previous Close | 2.06 |
| Open | 2.04 |
| Day High | 2.16 |
| Day Low | 2.04 |
| 52-Week High | 4.2 |
| 52-Week Low | 1.87 |
| Volume | 42,857 |
| Average Volume | 66,976 |
| Market Cap | 18.39M |
| PE | -0.94 |
| EPS | -2.23 |
| Moving Average 50 Days | 2.4 |
| Moving Average 200 Days | 2.46 |
| Change | 0.04 |
If you invested $1000 in Lisata Therapeutics, Inc. (LSTA) 10 years ago, it would be worth $11.38 as of November 11, 2025 at a share price of $2.1. Whereas If you bought $1000 worth of Lisata Therapeutics, Inc. (LSTA) shares 5 years ago, it would be worth $95.24 as of November 11, 2025 at a share price of $2.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
GlobeNewswire Inc.
Nov 06, 2025 1:00 PM GMT
Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the WorldBASKING RIDGE, N.J. , Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage ph
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
GlobeNewswire Inc.
Nov 04, 2025 9:00 PM GMT
Data from Catalent’s preclinical studies evaluating certepetide as a SMARTag® ADC payload showed both improved tumor selective penetration and efficacy BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA)
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
GlobeNewswire Inc.
Oct 30, 2025 12:00 PM GMT
BASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and othe